Brief: Kiromic Announces Identification Of Novel Targets For Allogeneic Car Gamma Delta T-Cell Therapy In Solid Tumors
21/05/2021 13:04
May 21 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC ANNOUNCES IDENTIFICATION OF NOVEL TARGETS FOR
ALLOGENEIC
CAR GAMMA DELTA T-CELL THERAPY IN SOLID TUMORS UTILIZING
KIROMIC’S PROPRIETARY ARTIFICIAL INTELLIGENCE ENGINE
* KIROMIC BIOPHARMA INC - NEW TARGETS INCLUDE NOVEL EPITOPES
OF
NY-ESO-1 AND A CANCER SELECTIVE ISOFORM SPLICE VARIANT OF
MESOTHELIN
Source text for Eikon: ID:nBw6hbzHGa
Further company coverage: KRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site